{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:04:11Z","timestamp":1784714651223,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12325-023-02528-8","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T01:01:44Z","timestamp":1687136504000},"page":"3574-3587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16"],"prefix":"10.1007","volume":"40","author":[{"given":"Jacob P.","family":"Thyssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Grond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"issue":"4s","key":"2528_CR1","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","volume":"139","author":"T Bieber","year":"2017","unstructured":"Bieber T, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? J Allergy Clin Immunol. 2017;139(4s):S58-s64.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2528_CR2","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","volume":"147","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, et al. Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174-1190.e1.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2528_CR3","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jaad.2016.07.016","volume":"75","author":"R Kantor","year":"2016","unstructured":"Kantor R, et al. Research letter: impact of pruritus on quality of life\u2014a systematic review. J Am Acad Dermatol. 2016;75(5):885-886.e4.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2528_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.anai.2021.03.019","volume":"127","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, et al. Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study. Ann Allergy Asthma Immunol. 2021;127(1):83-90.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2528_CR5","unstructured":"Olumiant. European Union Summary of Product Characteristics. Eli Lilly and Company. 2021 [cited 2023 10 February]; https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-productinformation_en.pdf. \nAccessed 10 Feb 2023."},{"issue":"9","key":"2528_CR6","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"2528_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333\u201343.","journal-title":"JAMA Dermatol"},{"key":"2528_CR8","doi-asserted-by":"crossref","unstructured":"Cleophas TJZ, Aeilko H. Regression trees: classification and regression tree (CART) models. In: Regression analysis in medical research. 2021; Springer International Publishing, p. 383\u2013391.","DOI":"10.1007\/978-3-030-61394-5_22"},{"key":"2528_CR9","unstructured":"Terry Therneau [aut], et al. Recursive Partitioning and Regression Trees. 2022 27 January 2023]; https:\/\/cran.r-project.org\/web\/packages\/rpart\/rpart.pdf. Accessed 27 Jan 2023."},{"issue":"2","key":"2528_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242\u201355.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2528_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/bjd.16078","volume":"178","author":"PP Vakharia","year":"2018","unstructured":"Vakharia PP, et al. Severity strata for five patient-reported outcomes in adults with atopic dermatitis. Br J Dermatol. 2018;178(4):925\u201330.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2528_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s13555-021-00640-7","volume":"12","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, et al. Clinical tailoring of baricitinib 2 mg in atopic dermatitis: baseline body surface area and rapid onset of action identifies response at week 16. Dermatol Ther. 2022;12(1):137\u201348.","journal-title":"Dermatol Ther"},{"issue":"6","key":"2528_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14439","volume":"33","author":"JP Thyssen","year":"2020","unstructured":"Thyssen JP, et al. Treatment of adult atopic dermatitis patients according to disease characteristics and demographics. Dermatol Ther. 2020;33(6): e14439.","journal-title":"Dermatol Ther"},{"issue":"6","key":"2528_CR14","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/jdv.16078","volume":"34","author":"A Heratizadeh","year":"2020","unstructured":"Heratizadeh A, et al. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. J Eur Acad Dermatol Venereol. 2020;34(6):1263\u201372.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"2528_CR15","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3390\/healthcare9111575","volume":"9","author":"G Radi","year":"2021","unstructured":"Radi G, et al. Baricitinib: the first Jak inhibitor approved in europe for the treatment of moderate to severe atopic dermatitis in adult patients. Healthcare (Basel). 2021;9(11):1575.","journal-title":"Healthcare (Basel)"},{"key":"2528_CR16","unstructured":"www.ema.europa.eu. Olumiant 2mg and 4mg film-coated tablets -Summary of Product Characteristics (SPC)-(eMC). 2020. 26 January 2023]; https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant#product-information-section. Accessed 26 Jan 2023."},{"issue":"4","key":"2528_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/1346-8138.16350","volume":"49","author":"A Uchiyama","year":"2022","unstructured":"Uchiyama A, et al. Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: a single-center retrospective study. J Dermatol. 2022;49(4):469\u201371.","journal-title":"J Dermatol"},{"key":"2528_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16763","author":"T Hagino","year":"2023","unstructured":"Hagino T, et al., Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2023. https:\/\/doi.org\/10.1111\/1346-8138.16763","journal-title":"J Dermatol"},{"issue":"4","key":"2528_CR19","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1111\/jdv.18804","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, et al. Short-term real-world experience with baricitinib treatment in Danish adults with moderate-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(4):e543\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2528_CR20","doi-asserted-by":"publisher","first-page":"adv00820","DOI":"10.2340\/actadv.v102.3978","volume":"102","author":"CM Boesjes","year":"2022","unstructured":"Boesjes CM, et al. Daily practice experience of baricitinib treatment for patients with difficult-to-treat atopic dermatitis: results from the BioDay Registry. Acta Derm Venereol. 2022;102:adv00820.","journal-title":"Acta Derm Venereol"},{"key":"2528_CR21","doi-asserted-by":"publisher","first-page":"adv00677","DOI":"10.2340\/actadv.v102.1088","volume":"102","author":"D Rogner","year":"2022","unstructured":"Rogner D, Biedermann T, Lauffer F. Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience. Acta Derm Venereol. 2022;102:adv00677.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"2528_CR22","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s13555-022-00734-w","volume":"12","author":"MS de Bruin-Weller","year":"2022","unstructured":"de Bruin-Weller MS, et al. Indirect treatment comparison of baricitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2022;12(6):1481\u201391.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"2528_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.sder.2011.05.002","volume":"30","author":"J Hong","year":"2011","unstructured":"Hong J, et al. Management of itch in atopic dermatitis. Semin Cutan Med Surg. 2011;30(2):71\u201386.","journal-title":"Semin Cutan Med Surg"},{"issue":"3","key":"2528_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40257-017-0335-4","volume":"19","author":"J Pavlis","year":"2018","unstructured":"Pavlis J, Yosipovitch G. Management of itch in atopic dermatitis. Am J Clin Dermatol. 2018;19(3):319\u201332.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"2528_CR25","doi-asserted-by":"publisher","first-page":"2161812","DOI":"10.1080\/09546634.2022.2161812","volume":"34","author":"T Bieber","year":"2023","unstructured":"Bieber T, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatolog Treat. 2023;34(1):2161812.","journal-title":"J Dermatolog Treat"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02528-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02528-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02528-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T03:25:13Z","timestamp":1688959513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02528-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2528"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02528-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]},"assertion":[{"value":"9 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}